Hurler syndrome
Hurler syndrome (also known as Mucopolysaccharidosis type I, MPS I, or Hurler's disease) is a genetic disorder that results from the buildup of glycosaminoglycans (GAGs) due to a deficiency of the enzyme alpha-L-iduronidase. This enzyme deficiency leads to a range of symptoms and physical abnormalities.
Signs and Symptoms[edit | edit source]
Individuals with Hurler syndrome typically exhibit symptoms within the first year of life. Common signs and symptoms include:
- Developmental delay
- Coarse facial features
- Enlarged liver and spleen (Hepatosplenomegaly)
- Corneal clouding
- Joint stiffness
- Hearing loss
- Cardiac issues, such as valvular heart disease
Genetics[edit | edit source]
Hurler syndrome is inherited in an autosomal recessive manner. This means that an affected individual must inherit two copies of the defective gene, one from each parent. The gene responsible for Hurler syndrome is located on chromosome 4p16.3 and encodes the enzyme alpha-L-iduronidase.
Diagnosis[edit | edit source]
Diagnosis of Hurler syndrome is typically based on clinical presentation and confirmed through enzyme assay tests that measure the activity of alpha-L-iduronidase. Genetic testing can also identify mutations in the IDUA gene.
Treatment[edit | edit source]
There is no cure for Hurler syndrome, but treatments are available to manage symptoms and improve quality of life. These include:
- Enzyme replacement therapy (ERT) with laronidase
- Hematopoietic stem cell transplantation (HSCT)
- Symptomatic treatments, such as surgeries for heart and skeletal issues
Prognosis[edit | edit source]
The prognosis for individuals with Hurler syndrome varies. Without treatment, life expectancy is significantly reduced, often not extending beyond the first decade of life. With early intervention, particularly with HSCT, some individuals may live into adolescence or adulthood.
History[edit | edit source]
Hurler syndrome was first described by German pediatrician Gertrud Hurler in 1919. It is one of several types of Mucopolysaccharidosis disorders, which are collectively known as lysosomal storage diseases.
See Also[edit | edit source]
- Mucopolysaccharidosis
- Lysosomal storage disease
- Enzyme replacement therapy
- Hematopoietic stem cell transplantation
Related Pages[edit | edit source]
- Mucopolysaccharidosis
- Lysosomal storage disease
- Enzyme replacement therapy
- Hematopoietic stem cell transplantation
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD